BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Gross Margin of 37.38% for Q1 2026, down 12905.0% year-over-year from N/an in Q1 2025, and down 142.72% quarter-over-quarter from 87.5% in Q4 2025.
BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Gross Margin history runs 5 years deep, the most recent figure standing at 37.38% for Q1 2026.
- In Q1 2026, Gross Margin fell 12905.0% year-over-year to 37.38%; the TTM figure through Mar 2026 stood at 36.32% (up 4853.0% YoY), while the FY2025 annual figure was 74.45%, up 6903.0% from the prior year.
- Gross Margin for Q1 2026 stood at 37.38%, down from 87.5% in the prior quarter.
- The five-year high for Gross Margin was 96.22% in Q4 2022, with the low at 446.73% in Q3 2024.
- The 5-year median for Gross Margin is 87.5% (2025), against an average of 5.74%.
- The sharpest annual moves came in 2024 and 2025: Gross Margin slumped 39658 bps in 2024, then surged 53550 bps in 2025.
- BioXcel Therapeutics' Gross Margin stood at 96.22% in 2022, then plunged by 193 bps to 89.89% in 2023, then slumped by 42 bps to 127.32% in 2024, then surged by 169 bps to 87.5% in 2025, then tumbled by 143 bps to 37.38% in 2026.
- Business Quant data shows BTAI's Gross Margin at 37.38% in Q1 2026, 87.5% in Q4 2025, and 88.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | 87.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.91% |
| Mar 31, 2026 | -37.38% |
| Dec 31, 2025 | 87.50% |
| Sep 30, 2025 | 88.78% |
| Jun 30, 2025 | 10.83% |
| Mar 31, 2025 | 91.67% |
| Dec 31, 2024 | -127.32% |
| Sep 30, 2024 | -446.73% |
| Jun 30, 2024 | 94.38% |
| Mar 31, 2024 | 86.25% |
| Dec 31, 2023 | -89.89% |
| Sep 30, 2023 | -50.15% |
| Jun 30, 2023 | 94.31% |
| Mar 31, 2023 | 95.63% |
| Dec 31, 2022 | 96.22% |
| Sep 30, 2022 | 91.97% |